BridgeBio Pharma, Inc. BBIO
Updated: 11 Aug 2026
No signal published yet
We already track BridgeBio Pharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow BridgeBio Pharma, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow BridgeBio Pharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 10, 2026, BridgeBio reported its second-quarter 2026 financial results, with total revenues reaching $243.7 million driven by sales of Attruby. The company also confirmed that three New Drug Applications have been submitted to the U.S. FDA for regulatory review.
What Firelda Watch includes for BridgeBio Pharma, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow BridgeBio Pharma, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow BridgeBio Pharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more